1 How soon should patients be eligible for differentiated service delivery models for antiretroviral

2 treatment? Evidence from Zambia

3 Short title: Outcomes of early DSD enrolment

- 4 Lise Jamieson^{1,2}, Sydney Rosen^{1,3}, Bevis Phiri⁴, Anna Grimsrud⁵, Muya Mwansa⁶, Hilda Shakwelele⁴,
- 5 Prudence Haimbe⁴, Mpande M Mwenechanya⁷, Priscilla Lumano-Mulenga⁶, Innocent Chimboma⁶,
- 6 Brooke E Nichols^{1,2,3*}
- 7
- 8 ¹Health Economics and Epidemiology Research Office (HE²RO), Department of Internal Medicine, Faculty of
- 9 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- ¹⁰ ²Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands
- ³Department of Global Health, Boston University School of Public Health, Boston, MA, USA
- 12 ⁴Clinton Health Access Initiative, Lusaka, Zambia
- 13 ⁵International AIDS Society, Cape Town, South Africa
- 14 ⁶Ministry of Health, Lusaka, Zambia
- 15 ⁷The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
- 16

17

- 18 *Corresponding author: Brooke Nichols (brooken@bu.edu); Department of Global Health, Boston
- 19 University School of Public Health, 801 Massachusetts Avenue, Boston, MA, USA.Tel:+1 857-544-
- 20 7250

- 22 E-mail addresses of authors:
- 23 LJ: <u>ljamieson@heroza.org</u>
- 24 SR: <u>sbrosen@bu.edu</u>
- 25 BP: <u>bphiri@clintonhealthaccess.org</u>
- 26 AG: <u>anna.grimsrud@iasociety.org</u>
- 27 MM: muya.mwansa@gmail.com
- 28 HS: <u>hshakwelele@clintonhealthaccess.org</u>
- 29 PH: phaimbe@clintonhealthaccess.org
- 30 MMM: <u>Mpande.Mwenechanya@cidrz.org</u>
- 31 PLM: priscillalloyd2@icloud.com

32 <u>IC: innocent.Chiboma@moh.gov.zm</u>

33 BEN: <u>brooken@bu.edu</u>

34

35 Keywords: differentiated service delivery (DSD) models, HIV, antiretroviral treatment, retention in

- 36 care, DSD guidelines
- 37
- 38 Word count:
- 39 Abstract: 266/350
- 40 Main text: 2,763/3,500

41 Abstract

42 Introduction: Attrition from HIV treatment is high during patients' first 6 months after antiretroviral 43 therapy (ART) initiation and patients with less than 6 months on ART are systematically excluded 44 from most differentiated service delivery (DSD) models, which are intended to reduce attrition. 45 Despite eligibility criteria requiring greater than 6 months on ART, some patients enroll earlier. Using 46 routinely-collected medical record data in Zambia, we compared loss to follow-up (LTFU) among patients enrolling in DSD models early (<6 months on ART) to LTFU among those who enrolled 47 48 according to guidelines (≥ 6 months on ART) in order to assess whether the ART experience eligibility 49 criterion is necessary.

50

51 **Methods**: We extracted data from electronic medical records for adults (\geq 15 years) who initiated 52 ART between 01/01/2019 and 31/12/2019 and evaluated LTFU, defined as >90 days late for last 53 scheduled medication pickup, at 18 months for "early enrollers" (DSD enrolment after <6 months on 54 ART) and "established enrollers" (DSD enrolment after \geq 6 months on ART). We used a log-binomial 55 model to compare LTFU risk between groups, adjusting for age, sex, urban/rural status, ART refill 56 interval and DSD model.

57

Results: For 6,340 early enrollers and 25,857 established enrollers there were no important differences between the groups in sex (61% female), age (median 37 years), or setting (65% urban). ART refill intervals were longer for established vs early enrollers (72% vs 55% were given 4–6month refills). LTFU at 18 months was 3% (192/6,340) for early enrollers and 5% (24,646/25,857) for established enrollers. Early enrollers were 41% less likely to be LTFU than established patients (adjusted risk ratio [95% confidence interval] 0.59 [0.50-0.68]).

65 **Conclusions**: Patients enrolled in DSD models in Zambia with < 6 months on ART were more likely

to be retained in care than patients referred after they were established on ART. A limitation of the

analysis is that early enrollers may have been selected for DSD participation due to providers' and

68 patients' expectations about future retention. Offering DSD model entry to at least some ART patients

- 69 <6 months after ART initiation may help address high attrition during the early treatment period.
- 70

71 Introduction

A critical step toward achieving universal coverage of antiretroviral therapy (ART) for HIV is to support lifelong patient retention in ART programmes. Data from sub-Saharan Africa (SSA), where some 70% of the world's ART patients reside, continue to indicate insufficient retention on ART [1], with about a fifth of all patients lost to care five years after treatment initiation [2]. A patient's first six months after initiation are a high risk period for attrition: a Zambian study showed rates of loss to follow-up to be four-fold higher in the first six months of ART treatment compared to the period between six months and 3.5 years thereafter [3].

79

80 Since 2016, the World Health Organization (WHO) has recommended differentiated service delivery 81 (DSD) for HIV treatment [4]. DSD models such as facility-based individual "fast track" medication 82 pickup and community-based ART refills can increase access and remove barriers to care by adjusting 83 the cadre of provider, location of service delivery, frequency of interactions with the healthcare 84 system, and/or types of services offered to support long-term retention of people established on HIV 85 treatment [5]. A recent systematic review reporting on outcomes of patients in DSD models in SSA 86 found that retention in care of those in DSD models was generally within 5% of that for conventional 87 care [6]. In Zambia, several DSD models have shown to have similar rates of retention as 88 conventional care 12 months after DSD model entry [7,8]. The INTERVAL trial, a cluster-89 randomized, non-inferiority trial conducted in Malawi and Zambia, found that 6-month ART 90 dispensing was non-inferior in terms of 12-month retention, compared to standard of care [8]. DSD 91 models have consistently been found to save substantial time and money for patients themselves, and 92 satisfaction with the models among both providers and patients has been high [8-10].

93

A major limitation of DSD models to date has been eligibility criteria that limit model enrollment to patients on the standard first-line ART regimen who are "stable" or "established on treatment," defined as having been on ART for at least 6 or 12 months and having documented viral suppression [8,11–13]. Until April 2021, the WHO's definition of "established" included at least 12 months of ART experience; new guidelines require at least 6 months on ART for DSD model eligibility [14].

99 Patients who are newly initiated on ART are thus systematically excluded from stable-patient-specific 100 DSD models and from the benefits they offer. In the previously cited INTERVAL trial in Malawi and 101 Zambia, 10% of all patients were excluded due to having initiated ART less than 6 months prior[15]. 102 For patients not eligible for DSD models, guidelines typically require frequent visits to the healthcare 103 facility and medication dispensing intervals of no more than 3 months [16]. In Zambia, all care is 104 differentiated and dependent on the needs of the patient [11], but currently there is no evidence on the 105 outcomes of patients with <6 months ART experience who enroll into DSD models that are typically 106 reserved for stable patients.

107

Despite existing guidelines limiting DSD eligibility based on time on ART, in practice patients who do not meet guideline-recommended criteria are sometimes enrolled in DSD models for stable patients, due to provider decision, error or patient request. To begin to understand how such patients who are referred early to DSD models fare when participating in DSD models designed for those established on treatment, we analyzed routinely collected medical record data from Zambia to compare rates of retention among patients enrolled into DSD models earlier than guidelines recommend with retention among those who met all eligibility criteria.

115

116 Methods

117 Study population and outcomes

Data were retrospectively extracted in October 2021 from SmartCare, Zambia's national electronic medical record system [17]. We extracted data for patients, aged 15 years or older, reported to have initiated ART between January 2019 and December 2020 at any of 692 health facilities across all 10 provinces. Zambian policy guidelines for this period required patients to be stable on ART before they are considered for DSD enrolment, with stability defined in the 2018 consolidated ART guidelines [11,12] as on ART for at least six months.

125 We defined patients who enrolled into a DSD model with <6 months of ART as "early enrollers", 126 while a comparison group of patients who enrolled into a DSD model with ≥ 6 months of ART as 127 "established enrollers". Patients on second-line ART (defined as those dispensed protease inhibitors 128 such as lopinavir, atazanavir or ritonavir) were excluded from this analysis, as they are already known 129 to be at high risk of attrition [18,19]. For both early and established enrollers, we assessed loss to 130 follow-up (LTFU) at 18 months post-ART initiation, with LTFU defined as patients who were 131 reported as "lost to follow-up" or "inactive" in the SmartCare database between 15 and 21 months 132 after ART initiation date. "Inactive" was defined as having missed a scheduled visit by more than 30 133 days. Rates of LTFU were calculated for early and established enrollers and stratified by DSD model 134 type and ART dispensing duration. DSD models, which had multiple names in the SmartCare 135 database, were grouped into the following categories: 1) adherence groups (community adherence 136 groups, rural/urban adherence groups); 2) extended clinic hours (DSD models designed for clinic 137 access before/after hours or weekends, including scholar models); 3) fast-track (procedures to 138 accelerate dispensing at clinics); 4) home ART delivery; 5) multi-month dispensing (MMD); and 6) 139 community pick-up point (central dispensing units, community retail pharmacies, community ART 140 distribution points, health posts, mobile ART distribution models) (Table 1).

142 Table 1. Differentiated service delivery (DSD) models for HIV treatment in use in Zambia

143 during the study period

Category	Model(s) in category	Description	
Adherence	Community adherence	Patient groups, consisting of ± 6 members, meeting at an agreed time every	
groups	groups	1-3 months. The groups are managed by the patients themselves, and usually	
		meet outside of the health facility. Members collect ART at clinical appoints	
		for other members in a rotating fashion [7].	
	Rural and urban adherence	Patient groups, consisting of 20-30 members, meeting at an agreed time	
	groups/clubs	every 2-3 months. Groups are often facilitated by the same health care	
		worker or facility-based volunteer, also providing pre-packaged ART [7].	
Community	Central dispensing units	A centralized model for ART distribution, where medication is packed at a	
pick-up point		centrally located hub and distributed to patients at multiple approved pick-	
		up points. Clinic visits occur every 6 months at the health facility [11].	
	Community ART	ART refills are provided to patients outside of health facilities, e.g. schools,	
	distribution points,	churches, community centres, community retail pharmacies and health posts	
	community retail	[11].	
	pharmacies, health posts		
	Mobile ART distribution	A clinical outreach team linked to a facility does 3-monthly clinical	
	models	assessments at community distribution points. This model is usually used for	
		hard-to-reach areas [11].	
Extended	Before/after-hours models,	These models allow patients to have a clinical visit and collect their ART	
clinic hours	weekend models, scholar	outside the conventional operation times at the facility (early mornings,	
	models	evenings and over weekends). These are beneficial to patients with	
		competing priorities (e.g. school or employment).	
Fast-track	Fast-track	A model that typically involves a separate, shorter queue to dispense ART to	
		stable patients, allowing for a quick patient visit when a clinical visit is not	
		required [20]	
Home ART	Home ART delivery	Trained community health workers (CHWs) linked to facilities conduct	
delivery		home visits to deliver ART, conduct health screening, monitor adherence,	
		and refer patients as required [7].	
Multi-month	Multi-month dispensing	Facility-based model in which the primary goal is to dispense medications	
dispensing		for more than one month (usually 6 months). Dispensing is typically done	
		during a clinical facility-based visit.	

1	4	4
-	-	-

145 Statistical analysis

We described the demographics of our study population using descriptive statistics. We compared loss to follow-up risk between early enrollers and established enrollers and Wilson's score interval was used to calculate 95% confidence intervals around proportions. We used a log-binomial regression to calculate risk ratios for loss to follow-up, adjusting for age, sex, urban/rural status, DSD model type and ART dispensing duration. We also conducted an age-stratified analysis and a subanalysis restricted to facilities with a higher proportion of early enrollers, with results shown in the Supplementary Appendix.

153

154 Ethics

This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030, the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number M190453, and the Boston University IRB H-38823 for the use of data with a waiver of consent.

159


160 Results

161 *Study populations*

162 The full SmartCare data set included 1,520,125 unique patients on ART over 2018-2021, of which 163 32,197 patients had enrolled into a DSD model after ART initiation and had an 18-month outcome 164 reported within the 15-to-21-month window (Figure 1). Of these, 6,340 patients were reported to have 165 been enrolled in DSD models <6 months after ART initiation during the study period (early enrollers). 166 The remaining 25,857 patients comprised the comparison group of established enrollers. For early 167 enrollers, median time enrolled in a DSD model at the time of outcome evaluation was 14.7 months 168 (IQR 13.0-16.5); majority (81%, n=20,856) of established enrollers were on DSD models at outcome 169 evaluation at a median of 5.8 months (interquartile range (IQR) 2.9-8.9) (Table 2). Early enrollers and 170 established enrollers were similar with respect to age, sex and urban/rural location. Across both

- 171 groups, the median age was 37 years (IQR 29 44), a majority (61%, 19,580/32,197) were female
- and most patients resided in urban settings (64%, n=20,618).
- 173

174 Figure 1: Flow diagram depicting study population



Variable		Early enrollers of DSD models (N=6,340)	Established enrollers of DSD models (N=25,857)
Age in years, median (IQR)		36 (29-44)	37 (29-44)
Age group	15-24	727 (11%)	2,589 (10%)
	25-34	2,069 (33%)	8,346 (32%)
	35-49	2,658 (42%)	11,424 (44%)
	50+	885 (14%)	3,487 (13%)
Sex	Female	3,914 (62%)	15,666 (61%)
	Male	2,426 (38%)	10,191 (39%)
Location	Rural	2,501 (39%)	9,078 (35%)
	Urban	3,839 (61%)	16,779 (65%)
Year of ART	2019	2,897 (46%)	17,346 (67%)
initiation	2020	3,443 (54%)	8,511 (33%)
DSD type	Adherence groups	149 (2%)	508 (2%)
	Community pickup points	671 (11%)	1,461 (6%)
	Extended clinic hours	85 (1%)	97 (<1%)
	Fast-track	979 (15%)	6,266 (24%)
	Home ART delivery	355 (6%)	973 (4%)
	Multi-month dispensing	4,101 (65%)	16,552 (64%)
ART months	<2 months	636 (10%)	1,476 (6%)
dispensed	3 months	2,197 (35%)	5,688 (22%)
	4-6 months	3,507 (55%)	18,679 (72%)
Outcome Year	2020	2,863 (45%)	17,283 (67%)
	2021	3,477 (55%)	8,574 (33%)
Months on ART at o	outcome, median (IQR)	17.9 (16.4-19.5)	18.4 (16.7-19.8)
On DSD at	Yes	6,340 (100%)	20,856 (81%)
outcome	No	0 (0%)	5,001 (19%)
Months on DSD at o	outcome, median (IQR)	14.7 (13.0-16.5)	5.8 (2.9-8.9)
Patient outcomes	On treatment	6,133 (97%)	24,646 (95%)
by 18 months after	Died	11 (<1%)	31 (<1%)
ART initiation	Lost to follow-up	192 (3%)	1,169 (5%)
	Stopped ART	4 (<1%)	10 (<1%)
	Stopped DSD	0 (0%)	1 (<1%)

177 Table 2. Demographics of patients enrolled in differentiated service delivery models

179	Most patients were enrolled in either multi-month dispensing DSD models (65% [n=4,101] of early
180	enrollers and 64% [n=16,552] of established enrollers) or fast-track (15% [n=979] of early enrollers
181	and 24% [n=6,266] of established enrollers) (Table 1). Amongst early enrollers, around half (55%,
182	n=3,477) were dispensed 4-6 months of ART at their most recent ART pickup, 35% (n=2,197) were
183	dispensed 3 months of ART, and 10% (n=636) were dispensed <2 months of ART. Established
184	enrollers had slightly longer dispensing intervals with 72% (n=18,679) dispensed 4-6 months of ART,

185 22% (n=5,688) dispensed 3 months of ART, and 6% (n=1,476) dispensed <2 months of ART (Table

186 1).

- 187
- 188 *Outcomes*

189 Early enrollers had a slightly lower rate of loss to follow-up (3.0% [95% confidence interval (CI) 190 2.6%-3.5%]) compared to the established enrollers (4.5% [4.3%-4.8%]) (Table 3). Early enrollers 191 experienced similar or lower loss to follow-up rates than established enrollers across nearly all 192 differentiated models of care. The exception was extended clinic hours: early enrollers enrolled in the 193 extended clinic hours model had a similar rate of loss to follow-up than established enrollers (10.6%; 194 [5.7%-18.9%] vs. 8.2% [4.2%-15.4%], respectively). Across both early and established enrollers, 195 longer dispensing periods were associated with lower rates of loss to follow-up, which increased from 196 2.5%-3.8% for 4-6-month dispensing to 3.5%-5.3% for 3-month dispensing to 4.1%-10.6% for <2-197 month dispensing (Table 3). Early enrollers with <2 months dispensing had a lower rate of loss to 198 follow-up than did established enrollers (4.1%; [2.8%-5.9%] vs. 10.6% [9.1%-12.2%]).

199

200 Table 3. Proportion of patients lost to follow-up at 18 months after ART initiation, stratified by

201 differentiated service delivery (DSD) model and ART months dispensed (95% confidence interval

202 *in round brackets, sample numbers in square brackets)*


	Early enrollers	Established enrollers
Overall	3.0% (2.6% - 3.5%)	4.5% (4.3% - 4.8%)
	[192/6,340]	[1,169/25,857]
By DSD model		
Adherence groups	2.7% (1% - 6.7%)	3.1% (1.9% - 5.1%)
- 1	[4/149]	[16/508]
Community pickup points	4.5% (3.1% - 6.3%)	3.3% (2.5% - 4.3%)
	[30/671]	[48/1,461]
Extended clinic hours	10.6% (5.7% - 18.9%)	8.2% (4.2% - 15.4%)
	[9/85]	[8/97]
Fast track	3.4% (2.4% - 4.7%)	3.6% (3.2% - 4.1%)
	[33/979]	[227/6,266]
Home ART delivery	1.4% (0.6% - 3.3%)	6.3% (4.9% - 8%)
	[5/355]	[61/973]
Multi-month dispensing	2.7% (2.3% - 3.2%)	4.9% (4.6% - 5.2%)
	[111/4,101]	[809/16,552]
By months ART dispensed		

	Early enrollers	Established enrollers
<2 months	4.1% (2.8% - 5.9%)	10.6% (9.1% - 12.2%)
	[26/636]	[156/1,476]
3 months	3.5% (2.8% - 4.4%)	5.3% (4.8% - 5.9%)
	[77/2,197]	[303/5,688]
4-6 months	2.5% (2.1% - 3.1%)	3.8% (3.5% - 4.1%)
	[89/3,507]	[709/18,679]

204	In an analysis adjusting for age, sex, location, and ART dispensing duration or DSD model type
205	(where applicable),, early enrollers in all DSD model types and dispensing durations were 41% less
206	likely to be lost to follow-up than established enrollers (adjusted risk ratio (aRR) 0.59 [0.50-0.68])
207	(Figure 2). The reduced adjusted risk of being lost to follow-up were similar for patients in adherence
208	groups (aRR 0.79 [0.23-2.12]), multi-month dispensing (aRR 0.51 [0.41-0.61]), home ART delivery
209	(aRR 0.18 [0.06-0.41]) and fast track models (aRR 0.74 [0.50-1.05]). Early enrollers had a statistically
210	insignificant increased risk of being lost to follow-up in the community pick-up point (aRR 1.30
211	[0.81-2.03]) and extended clinic hours models (aRR 1.19 [0.43-3.34]) compared to the established
212	enrollers.

214 Figure 2. Relative risk of loss to follow-up at 18 months post-ART initiation for early enrollers

- 215 of differentiated service delivery (DSD) models (reference group: established enrollers of DSD models
- 216 with >6 months of ART at DSD entry; analysis adjusted for age, sex, urban/rural status and number of months
- 217 dispensed (for DSD stratified analysis) and DSD model (for months dispensed stratified analysis))



218

219

An age-stratified analysis produced similar results to the main analysis, with early enrollers in each age group being less likely to be lost to follow-up than established enrollers in the same age group. However, the effect of earlier enrollment in DSD on reduced loss to follow-up appeared less pronounced in patients on 4-6 months' ART dispensing for those aged 25 to 49 years (Appendix Figure S1). In facilities where a larger proportion of all DSD patients enrolled in DSD models early, the trend towards early enrollers performing better persisted with respect to loss to follow-up compared to outcomes for established enrollers (Appendix Figure S2).

227

228 Discussion

In nearly all of sub-Saharan Africa, DSD model eligibility criteria require that patients be on ART fora minimum of six months (and in some countries a minimum of 12 months) prior to DSD model

enrollment [21]. We present novel data from Zambia highlighting good outcomes when newly
initiated ART patients (those with less than 6 months' ART experience) are referred early to DSD
models. Those referred early to DSD appear to have good outcomes across different DSD models and
age categories.

235

236 Our data begin to fill in a gap in the evidence base on the validity of time on treatment as an eligibility 237 criterion for DSD models. Because few if any countries permit DSD model enrollment for new 238 initiators, little evidence on their experience in DSD models has been available until now. To date, 239 most reports on DSD outcomes have been limited to people who have spent a significant amount of 240 time on ART prior to DSD model enrollment. In the previously mentioned INTERVAL trial, for 241 example, participants had been on ART for a median of roughly five years at DSD model entry, while 242 patients in a trial of multi-month dispensing in adherence clubs in South Africa had a median duration 243 on ART of 7.3 years at baseline [22].

244

245 While ART patients in Zambia have historically been lost to follow-up at high rates in the first few 246 months after ART initiation [3], in our DSD patient population this was less likely to be the case. Our 247 results provide evidence to support the recent revision of WHO guidelines that reduce time on ART 248 from 12 to six months on treatment as part the definition of "established" on ART [14]. These 249 findings offer reassurance and evidence to countries that have expanded eligibility as they scale up 250 DSD models [21,23], particularly to support uninterrupted access to HIV treatment during the 251 COVID-19 pandemic, that earlier referral to DSD is possible without compromising patient care. 252 Even if many, or most, of the patients in our "early enrollment" sample were selected deliberately 253 because they were considered at low loss to follow-up risk, our results demonstrate that early 254 eligibility for DSD models should be considered for at least some patients before they reach six 255 months on ART.

256

Loss to follow up at 18 months after ART initiation for early and established enrollers averaged 1-11% for all six categories of DSD models studied. We did not observe any programmatically

259 important differences by model or ART experience prior to model enrollment. Where a 260 programmatically important difference did arise, in contrast, was in dispensing intervals. Regardless 261 of how long a patient had been on ART at DSD model enrollment, patients who received ≤ 2 months 262 of medications at a time were more likely to be lost to follow up than patients who received either 3 263 months or 4-6 months of medications. This likely reflects providers' assessments of patients' ability to 264 remain on treatment and/or clinical condition. Those regarded as being at higher risk of attrition are 265 asked to come to the clinic for medication refills more often, so that they can be monitored and 266 supported more closely. Ironically, difficulty in accessing the clinic may be the very reason that some 267 patients are at high risk of attrition. For these patients, insisting on shorter refill durations may simply 268 exacerbate whatever challenges they face.

269

270 There were several limitations to our analysis. First, as noted above, we assume that patients with <6271 months on ART in our sample were not offered DSD model enrollment at random. If providers made 272 accurate clinical decisions about individual patients' risks of attrition, patients in our "early 273 enrollment" cohorts could over-represent patients thought to have low attrition risk. To achieve the 274 results we found, providers would have had to make these decisions correctly at multiple sites across 275 the entire country. If this is the case, our data suggest that the healthcare workers responsible for 276 enrolling patients into DSD models can successfully identify those who will do well with early 277 enrollment. At the same time, if the early enrollers in our data set do comprise patients at lower risk of 278 loss to follow-up, then our results likely underestimate the true rate of loss to follow-up that would 279 occur if early DSD enrollment were to be broadly available, without the benefit of provider selection.

280

A second limitation is that our data set included only patients reported in the electronic medical record system to have enrolled in a DSD model. It is possible that some patients not in DSD models may be recorded as enrolled, and some who were enrolled may have been missed. Third, bias could occur if facilities with better-than-average retention in care were also more likely to allow early DSD model enrollment. In this case, our results may reflect differences in facility quality, as well as enrollment timing. An analysis restricted to facilities with >20% early DSD enrolment showed an even lower risk

of loss to follow-up among patients enrolled early into DSD models, however, compared to patients
with >6 months of ART at DSD entry.

289

290 Despite these limitations, our analysis demonstrates that patients on ART for less than six months 291 who are enrolled in existing DSD models can be successfully retained in care and may even fare 292 better than those left in conventional care and only initiate DSD models greater than six months after 293 ART initiation. It is likely that not all patients are ready for less intensive DSD models in their first 294 half-year or year on treatment, but some clearly are. Since DSD models have been shown to be 295 beneficial to patients and in some cases to providers, offering enrollment to newly-initiating ART 296 patients may improve ART programs in general. Future research should look more closely at which 297 patients can be enrolled early and which models of care serve these patients best.

298

299 Conclusions

300 Current policy for DSD model eligibility criteria in Zambia, as in other countries, have required a 301 minimum of 12 months of ART before a patient is considered for DSD enrolment, and more recently, 302 a minimum of six months of ART. In order to change guidelines to allow DSD enrolment sooner after 303 ART initiation (i.e., 6 months or less), large-scale observational evidence, implementation research or 304 trial data demonstrating good patient outcomes among those who enrol in DSD models < six months' 305 post ART initiation would be required. This analysis therefore provides a critical first step towards the 306 reassessment of the delayed DSD enrolment policies, and signals that further research needs to be 307 conducted in other SSA countries to evaluate patient outcomes for early DSD model enrolment.

308

310 Competing interests

311 We declare no competing interests.

312 Authors' contributions

- LJ, BN, SR and AG conceptualized the study. BP, HS, PH, MM, PLM, IC curated data for the study.
- BP, HS, PH, MMM provided supervision of the study. LJ led data analysis and drafted the paper
- along with BN, SR and AG. All authors contributed to data interpretation and critically reviewed a
- revised draft of the manuscript. All authors have read and approved the final manuscript.

317 Acknowledgements

- 318 Funding: Funding for the study was provided by the Bill & Melinda Gates Foundation through
- 319 OPP1192640 to Boston University. The funder had no role in study design, data collection and
- analysis, decision to publish or preparation of the manuscript.
- 321 Data sharing: The data is owned by the Zambian Ministry of Health and the use of it was approved
- 322 by the Human Research Ethics Committee (University of Witwatersrand, Johannesburg, South Africa)
- 323 and ERES Converge IRB (Zambia). All relevant data is included in the paper and supplementary
- tables. The full data are available upon approval from Zambian Ministry of Health and appropriate
- 325 ethics committees.

327 **References**

- UNAIDS AIDSinfo: People living with HIV receiving ART [Internet]. 2020 [cited 2021 Jun 15]. Available from: https://aidsinfo.unaids.org/
- Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Intern AIDS Soc. 2018 Feb;21(2):e25084.
- Schöni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L, et al.
 Estimating Loss to Follow-Up in HIV-Infected Patients on Antiretroviral Therapy: The Effect of
 the Competing Risk of Death in Zambia and Switzerland. Myer L, editor. PLoS ONE. 2011 Dec
 19;6(12):e27919.
- World Health Organization. Guidelines on HIV self-testing and partner notification, supplement to consolidated guidelines on HIV testing services [Internet]. 2016 [cited 2020 Nov 18].
 Available from: https://www.who.int/hiv/pub/vct/hiv-self-testing-guidelines/en/
- 5. Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing
 HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int Health. 2015
 Apr;20(4):430–47.
- Long L, Kuchukhidze S, Pascoe S, Nichols BE, Fox MP, Cele R, et al. Retention in care and
 viral suppression in differentiated service delivery models for HIV treatment delivery in
 sub□Saharan Africa: a rapid systematic review. J Intern AIDS Soc [Internet]. 2020 Nov [cited
 2021 May 14];23(11). Available from: https://onlinelibrary.wiley.com/doi/10.1002/jia2.25640
- Nichols BE, Cele R, Jamieson L, Long LC, Siwale Z, Banda P, et al. Community-based delivery
 of HIV treatment in Zambia: costs and outcomes. AIDS. 2021 Feb 2;35(2):299–306.
- Hoffman RM, Moyo C, Balakasi KT, Siwale Z, Hubbard J, Bardon A, et al. Multimonth
 dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a
 cluster-randomised, non-blinded, non-inferiority trial. The Lancet Global Health. 2021
 May;9(5):e628–38.
- Nichols BE, Cele R, Lekodeba N, Tukei B, Ngorima I Mabhena N, Tiam A, et al. Economic
 evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to
 providers and patients. J Intern AIDS Soc [Internet]. 2021 Apr [cited 2021 Jun 1];24(4).
 Available from: https://onlinelibrary.wiley.com/doi/10.1002/jia2.25692
- Guthrie T, Muheki C, Greener R, Kanoowe S, Lagony S, Miot J, et al. Costs and outcomes of differentiated ART service delivery in Uganda: summary of findings. [Internet]. 2020. Available from: https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-costoutcomes-FINAL-2020.08.24.pdf
- 361 11. Ministry of Health. Zambia Differentiated Service Delivery Framework. 2018.
- Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and
 Prevention of HIV Infection. 2018.
- Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and
 Prevention of HIV Infection. 2020.

- World Health Organization. Updated recommendations on service delivery for the treatment and
 care of people living with HIV. [Internet]. 2021 Apr. Available from:
- 368 https://apps.who.int/iris/rest/bitstreams/1344311/retrieve
- Hoffman RM, Balakasi K, Bardon AR, Siwale Z, Hubbard J, Kakwesa G, et al. Eligibility for
 differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia.
 AIDS. 2020 Mar 1;34(3):475–9.
- Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a
 patient's first six months on antiretroviral therapy for HIV: an applied research agenda. Gates
 Open Res. 2020;4:116.
- 375 17. Gumede-Moyo S, Todd J, Bond V, Mee P, Filteau S. A qualitative inquiry into implementing an
 aretrospective study. BMJ Open. 2019 Sep;9(9):e030428.
- Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, et al. Tenofovir in
 Second-Line ART in Zambia and South Africa: Collaborative Analysis of Cohort Studies.
 JAIDS Journal of Acquired Immune Deficiency Syndromes. 2012 Sep 1;61(1):41–8.
- Kebede HK, Mwanri L, Ward P, Gesesew HA. Predictors of lost to follow up from antiretroviral
 therapy among adults in sub-Saharan Africa: a systematic review and meta-analysis. Infect Dis
 Poverty. 2021 Dec;10(1):33.
- Huber A, Pascoe S, Nichols B, Long L, Kuchukhidze S, Phiri B, et al. Differentiated Service
 Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape
 Analysis. Glob Health Sci Pract. 2021 May 10;ghsp;GHSP-D-20-00532v1.
- Time on ART before eligibility for DSD for HIV treatment. Differentiated Service Delivery.
 [Internet]. International AIDS Society (IAS); 2020. Available from: https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/
- 3901-Time%20to%20DSD%20Eligibility%20D5.pdf
- 22. Cassidy T, Grimsrud A, Keene C, Lebelo K, Hayes H, Orrell C, et al. Twenty-four-month
 outcomes from a cluster-randomized controlled trial of extending antiretroviral therapy refills in
 ART adherence clubs. J Int AIDS Soc. 2020 Dec;23(12):e25649.
- 394 23. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in
 395 sub Saharan Africa during COVID 19. J Int AIDS Soc [Internet]. 2021 Jun [cited 2021 Jul
 396 12];24(6). Available from: https://onlinelibrary.wiley.com/doi/10.1002/jia2.25704
- 397